DiscoveRx Launches ß-arrestin Assay Platform for High Throughput GPCR Screening

DiscoveRx Corporation, today announced the launch of their PathHunter™ ß-Arrestin Assay, a universal G-protein coupled receptor (GPCR) screening platform that utilizes a proprietary ProLink™ tag along with the well established enzyme fragment complementation (EFC) technology. This launch further strengthens DiscoveRx leadership position as a provider of GPCR assays.

Commenting on the launch Dr. Pyare Khanna , CEO of DiscoveRx said, "PathHunter™ ß-Arrestin Aassay is another revolutionary offering from DiscoveRx which further confirms our commitment to provide novel, chemiluminescent assays for both biochemical and cell based drug discovery research and screening. This product was developed in response to a market demand for a non-imaging, HTS technology for studying virtually any GPCR. With a product portfolio that includes ß-Arrestin technology, HitHunter™ cAMP assays, HitHunter IP3 assays, Calcium NW and Coelentrazine reagents, DiscoveRx is the only GPCR assay provider that offers best-in-class screening solutions for every major type of GPCR target."

The PathHunter™ cell based assay platform utilizing the ProLabel tag has proven to be an enabling system for drug discovery that provides a unique assay platform to measure protein expression, degradation, secretion and translocation for a variety of drug discovery target classes. With the launch of the ProLink™ tag and ß-Arrestin Assay, a whole new suite of PathHunter™ assays that revolve around protein-protein interaction will soon be possible.

DiscoveRx plans to offer the PathHunter™ ß-Arrestin technology as a standard package, without need of any licensing arrangements. Package includes Arrestin-EA cell lines, plasmids for introducing GPCR’s and screening reagents for one step, homogeneous chemiluminescent detection. Parties interested in this technology should contact their DiscoveRx Technical sales representative or visit our website via the article webpage.